Organon & Co.

Organon & Co. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Organon & Co. is an American pharmaceutical company specializing in reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia.

Ticker: OGN

Humankind Value: $42.0 B

Revenue: $9.4 B

Market Cap: $8.2 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Organon & Co. has earned a spot in our top 100. Notable sources of positive value are Pharmaceuticals ($27.5 B), Healthcare R&D ($11.4 B), and Economic Value ($2.9 B). Pharmaceutical R&D is one of the most important sources of gains to human life expectancy. The value associated with Pharmaceuticals and Healthcare R&D contains our estimation of 808,354.5 additional years lived by people worldwide. The firm creates economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. Organon & Co. can increase its Humankind Value by addressing Greenhouse Gases (-$717.8 M) and Air Pollution (-$144.5 M). Pharmaceuticals, Healthcare R&D, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings